|
|
|
|
| LEADER |
03871nam a2200397 u 4500 |
| 001 |
EB001874915 |
| 003 |
EBX01000000000000001038282 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
191026 r ||| eng |
| 020 |
|
|
|a 9788281212213
|
| 100 |
1 |
|
|a Ringerike, Tove
|
| 245 |
0 |
0 |
|a Efficacy and safety of angiotensin receptor blockers alone and in combination with diuretics in patients with hypertension, heart failure or diabetic nephropathy
|h Elektronische Ressource
|c Ringerike, Tove, Reikvam, Åsmund, Gjertsen, Marianne Klemp
|
| 260 |
|
|
|a Oslo
|b Norwegian Knowledge Centre for the Health Services
|c July 2008, 2008
|
| 300 |
|
|
|a 1 PDF file (pages 6-9)
|
| 653 |
|
|
|a Angiotensin Receptor Antagonists / therapeutic use
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Hypertension / drug therapy
|
| 653 |
|
|
|a Drug Therapy, Combination
|
| 653 |
|
|
|a Diabetic Nephropathies / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Angiotensin Receptor Antagonists / adverse effects
|
| 653 |
|
|
|a Sodium Chloride Symporter Inhibitors
|
| 653 |
|
|
|a Heart Failure / drug therapy
|
| 700 |
1 |
|
|a Reikvam, Åsmund
|e [author]
|
| 700 |
1 |
|
|a Gjertsen, Marianne Klemp
|e [author]
|
| 700 |
1 |
|
|a Ringerike, Tove
|
| 710 |
2 |
|
|a Nasjonalt kunnskapssenter for helsetjenesten
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 500 |
|
|
|a English summary excerpted from full report in Norwegian: Effekt og sikkerhet av angiotensin reseptorblokkere med og uten diuretika hos pasienter med hypertensjon, hjertesvikt eller diabetisk nefropati. - Excerpt from Review of systematic reviews no. 24-2008
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK464895
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a Neither did we find systematic reviews in which the combination drugs were compared. This applied to all clinical endpoints and all patient populations examined in this report. Studies that compared the different ARBs with other active drug treatments or with placebo, with use of hard endpoints (death, cardiovascular events, end stage renal failure), are present but few. For most comparisons with other active treatments significant differences with regard to efficacy have not been reported. Thus these studies could not be used as a basis for trying to undertake an indirect comparison between the different drugs within the ARB class. ARBs appeared to be well tolerated. The adverse events related to the ARBs varied between studies, and there were not sufficient data to determine whether differences existed between the different ARBs concerning specific adverse drug reactions.
|
| 520 |
|
|
|a Conclusion It has not been documented that one or several drugs within the class of ARB are more efficacious or safer than the others in patients with hypertension, heart failure or diabetic nephropathy
|
| 520 |
|
|
|a Background Hypertension increases the risk of developing cardiovascular diseases, in particular myocardial infarction and stroke. Several types of drugs lower blood pressure and angiotensin receptor blockers (ARB) constitute one drug class. These drugs are also found in combination with thiazide diuretics. This report aimed to compare the different drugs within the ARB class with regard to efficacy and safety in patients with hypertension, heart failure and diabetic nephropathy. Method The report is an overview of systematic reviews. We have examined the effect of ARB on clinical endpoints like death, cardiovascular events (myocardial infarct, stoke) and end-stage renal disease. We performed systematic searches in Cochrane Library, Centre for Reviews and Dissemination databases, Medline (Ovid) and Embase (Ovid). Results We did not identify systematic reviews where drugs within the ARB class were directly compared.
|